The effectiveness of Moderna’s COVID-19 vaccine against infection turns negative over time, according to a new study that was funded by the vaccine maker.
The effectiveness of three doses—a primary series and a booster—against infection remained above 50 percent after 150 days against BA.1, a subvariant of the Omicron virus variant, researchers estimated.
